Share on StockTwits

Equities research analysts at Goldman Sachs lifted their price objective on shares of EXACT Sciences (NASDAQ:EXAS) from $19.00 to $26.00 in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock. Goldman Sachs’ price target would indicate a potential upside of 22.47% from the company’s current price.

Shares of EXACT Sciences (NASDAQ:EXAS) opened at 21.23 on Wednesday. EXACT Sciences has a 52 week low of $9.53 and a 52 week high of $22.25. The stock’s 50-day moving average is $17.67 and its 200-day moving average is $14.95. The company’s market cap is $1.761 billion. EXACT Sciences also was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 26,442,496 shares, a growth of 4.9% from the July 31st total of 25,198,205 shares. Based on an average daily volume of 2,400,773 shares, the short-interest ratio is currently 11.0 days. Approximately 32.4% of the shares of the company are sold short.

EXACT Sciences (NASDAQ:EXAS) last released its earnings data on Tuesday, July 22nd. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities raised their price target on shares of EXACT Sciences from $22.00 to $28.00 in a research note on Wednesday, August 27th. They now have a “market outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $21.00 to $23.00 in a research note on Tuesday, August 26th. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, August 12th. They now have a $20.00 price target on the stock, up previously from $19.00. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of “Hold” and a consensus target price of $22.17.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Receive News & Ratings for EXACT Sciences Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co and related companies with Analyst Ratings Network's FREE daily email newsletter.